for complex conditions
Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer
About Peak Bio
Experienced management team with more than 50 plus years of industry experience in small molecules, antibodies, and antibody-drug-conjugates (ADC) drug development and has successfully forged companies that create best-in-class therapeutics during their tenures.
PHP-303 is a novel small molecule inhibitor of Neutrophil Elastase being investigated therapeutically for a rare and potentially life-threatening genetic condition called AATD.
ADCs are a class of anti-cancer that combine selectivity of monoclonal antibodies with the cytotoxic potential of small molecule therapeutics and targeted therapies.
Remembering Patricia Finn
It is with great sadness that we share the passing of our beloved employee, Dr. Patricia Finn, PhD. on Friday December 15, 2023. Dr. Finn was an integral part of the Peak Bio Research and Development team until her last day. She will truly be missed by all.Her family has set up a scholarship fund in lieu of service and flowers. Patricia Finn Obituary (1958 - 2023)